Soutenir la recherche

Publications et ressources

Trier par :
Afficher :
1-10 sur 79

French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes

P Cacoub, M Bourliere, T Asselah, V De Ledinghen, P Mathurin, Christophe HEZODE, L Henry, M Stepanova, ZM Younossi,

Value Health 01/10/2018;21(10) : 1218-1225 10.1016/j.jval.2018.01.006. 21/02/2018

Integrated Care for the Use of Direct-acting Antivirals in Patients With Chronic Hepatitis C and Substance Use Disorder

JB Trabut, C Barrault, H Charlot, D Carmona, A Bourdel, M Benslimane, Murielle FRANCOIS, W Kini-Matondo, R Causse, F Roudot-Thoraval, Christophe HEZODE,

J Addict Med 01/09/2018;12(5) : 346-352 10.1097/ADM.0000000000000415

High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.

M Puoti, GR Foster, S Wang, D Mutimer, E Gane, C Moreno, TT Chang, SS Lee, R Marinho, JF Dufour, S Pol, Christophe HEZODE, SC Gordon, SI Strasser, PJ Thuluvath, Z Zhang, S Lovell, T Pilot-Matias, FJ Mensa,

J Hepatol. 01/08/2018;69(2) : 293-300 10.1016/j.jhep.2018.03.007. 16/03/2018

Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1 or 4 and Prior Direct-acting Antiviral Treatment Failure

F Poordad, S Pol, A Asatryan, M Buti, D Shaw, Christophe HEZODE, F Felizarta, RW Reindollar, SC Gordon, S Pianko, MW Fried, D Bernstein, J Gallant, CW Lin, Y Lei, TI Ng, P Krishnan, S Kopecky-Bromberg, J Kort, FJ Mensa,

Hepatology. 01/06/2018;67(4) : 1253-1260 10.1002/hep.29671 30/01/2018

Long-Term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis.

P Cacoub, SN Si Ahmed, Y Ferfar, S Pol, D Thabut, Christophe HEZODE, L Alric, C Comarmond, G Ragab, L Quartuccio, M Hegazy, T Poynard, M Resche-Rigon, D Saadoun,

Clin Gastroenterol Hepatol. 29/05/2018;pii: S1542-3565(18) : 30553-6 10.1016/j.cgh.2018.05.021

Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies

Christophe HEZODE, N Reau, ES Svarovkaia, BP Doehle, R Shanmugam, H Dvory-Sobol, C Hedskog, J McNally, A Osinusi, DM Brainard, MD Miller, H Mo, SK Roberts, JG O'Leary, SD Shafran, S Zeuzem,

J Hepatol 01/05/2018;68(5) : 895-903 10.1016/j.jhep.2017.11.032. 06/12/2017

Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed a NS5A or NS3-containing regimen. ANRS HC34 REVENGE

V De Ledinghen, C Laforest, Christophe HEZODE, S Pol, A Renault, L Alric, D Larrey, S Metivier, A Tran, C Jezequel, D Samuel, F Zoulim, C Tual, A Pailhe, S Gibowski, M Bourliere, E Bellissant, Jean-Michel PAWLOTSKY,

Clin Infect Dis. 19/03/2018;66(7) : 1013-1018 10.1093/cid/cix916.

Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study

V De Ledinghen, C Laforest, Christophe HEZODE, S Pol, A Renault, L Alric, D Larrey, S Metivier, A Tran, C Jezequel, D Samuel, F Zoulim, C Tual, A Pailhe, S Gibowski, M Bourliere, E Bellissant, Jean-Michel PAWLOTSKY,

Clin Infect Dis. 19/03/2018;66(7) : 1013-1018 10.1093/cid/cix916.

Afficher :
1-10 sur 79